Ingo Mellinghoff

About

Ingo Mellinghoff, MD, FACP, is a physician-scientist whose laboratory focuses on the study of molecular pathways that regulate brain tumor growth. His long-term goal is to develop therapeutic paradigms that target specific properties of primary brain tumors, including genetic alterations in cancer signaling pathways, unique aspects of brain tumor metabolism, and interactions of brain tumor cells with their brain microenvironment. His research involves studies in experimental brain tumor models that are closely linked to the evaluation of novel agents in early-phase clinical trials. Dr. Mellinghoff has contributed to significant advancements in the treatment of low-grade gliomas, including the development and clinical testing of targeted drugs such as vorasidenib and ivosidenib, which reduce tumor-associated metabolites and show encouraging tumor responses. His work has led to the FDA approval of drugs for low-grade glioma with IDH gene mutations and has been published in high-impact journals. His research also explores the use of liquid biopsies from spinal fluid to guide brain tumor diagnosis and treatment, and he has been involved in studies tracking tumor evolution through cerebrospinal fluid analysis.

Research topics

• Internal medicine
• Oncology
• Medicine
• Cancer research
• Pathology
• Biology
• Engineering
• Genetics
• Intensive care medicine
• Medical physics

Selected publications

• Glioblastoma and Other Primary Brain Malignancies in Adults

  JAMA · 2023 · 1129 citations

  Senior authorCorresponding

  Importance: Malignant primary brain tumors cause more than 15 000 deaths per year in the United States. The annual incidence of primary malignant brain tumors is approximately 7 per 100 000 individuals and increases with age. Five-year survival is approximately 36%. Observations: Approximately 49% of malignant brain tumors are glioblastomas, and 30% are diffusely infiltrating lower-grade gliomas. Other malignant brain tumors include primary central nervous system (CNS) lymphoma (7%) and malignan…

  DOI

• Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

  Neuro-Oncology · 2020 · 1111 citations

  Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase w…

  DOI

• Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

  New England Journal of Medicine · 2023 · 683 citations

  1st authorCorresponding

  BACKGROUND: Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas. METHODS: In a double-blind, phase 3 trial, we randomly assigned patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery to receive either oral vorasidenib…

  DOI

• Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization

  Journal of Clinical Oncology · 2023 · 47 citations

  PURPOSE: The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for phase III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human epidermal growth factor receptor 2 inhibitor], and CC-115 [a deoxyribonucleic acid-dependent protein k…

  PublisherDOI

• Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors

  Neuro-Oncology · 2022 · 23 citations

  Imaging response assessment is a cornerstone of patient care and drug development in oncology. Clinicians/clinical researchers rely on tumor imaging to estimate the impact of new treatments and guide decision making for patients and candidate therapies. This is important in brain cancer, where associations between tumor size/growth and emerging neurological deficits are strong. Accurately measuring the impact of a new therapy on tumor growth early in clinical development, where patient numbers a…

  PublisherOA PDFDOI

Recent grants

• Molecular Mechanisms of IDH1-mediated Gliomagenesis

  NIH · $411k · 2012–2017

• Molecular Mechanisms of IDH1-mediated Gliomagenesis

  NIH · $1.6M · 2012–2018

• Molecular Mechanisms of Drug Resistance in Primary Brain Tumors

  NIH · $4.7M · 2018–2025

Frequent coauthors

• Patrick Y. Wen

  442 shared

• Timothy F. Cloughesy

  University of California, Los Angeles

  428 shared

• Carl Campos

  Memorial Sloan Kettering Cancer Center

  284 shared

• Michael D. Prados

  University of California, San Francisco

  251 shared

• Lisa M. DeAngelis

  Memorial Sloan Kettering Cancer Center

  241 shared

• Paul S. Mischel

  Stanford University

  205 shared

• Cameron Brennan

  172 shared

• John G. Kuhn

  University of California, Los Angeles

  172 shared

Labs

• The Ingo Mellinghoff LabPI

Similar researchers at Cornell University

• John Blenish-128
• Omar Abdel-Wahabh-118
• David Scheinbergh-102